GlassScriptPhysician profile
Marlo Caldevilla
NPI 1215538988
$4,368.79
in general payments reported to CMS, 2019-2025
20 companies · $577 in 2025
The $577 reported for 2025 was more than what 93% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $295 · 2023: $1,792 · 2024: $1,705 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,073.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $989.91 | 2022-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Jazz Pharmaceuticals INC. | $921.38 | 2022-2025 | |
| Noven Therapeutics, LLC | $373.71 | 2023-2025 | Xelstrym, Secuado |
| Corium, LLC | $330.15 | 2023-2024 | Azstarys |
| Ucb, INC. | $324.10 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Sumitomo Pharma America, INC. | $272.03 | 2023-2024 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $244.23 | 2023-2025 | Fycompa |
| Ironshore Pharmaceuticals INC. | $202.43 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $105.42 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $102.80 | 2023-2025 | Ingrezza, Ongentys |
| Eisai INC. | $102.37 | 2022-2023 | |
| Neurelis, INC. | $75.46 | 2023-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $73.72 | 2024-2025 | Daybue |
| Biogen, INC. | $57.27 | 2022-2024 | Spinraza |
| Neos Therapeutics, LP | $49.00 | 2022-2023 | Adzenys Xr-Odt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $42.39 | 2023 | Lyvispah |
| Biohaven Pharmaceutical Holding Company LTD. | $35.00 | 2022 | |
| Vertical Pharmaceuticals, LLC | $33.33 | 2024 | Relexxii |
| Noven Pharmaceuticals, INC. | $20.83 | 2023 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $13.26 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlo Caldevilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.